This panel will examine who dominates the IP landscape in biotech, holds patents that are derived from internal R&D efforts, or tend to augment the pipeline via licensing and M&A activities. Join us for an engaging discussion that will look at top patent holders in biotech, their strategies for portfolio growth, and how IP competitive intelligence affects deal-making.



Objectives:

Illustrate the impact M&A activity and corresponding patent holdings have on highly successful biotechs and their product pipelines.

Correlate patent and product pipeline activity with internal R&D efforts & patent in-licensing initiatives.

Examine the role of venture capital funding and how it influences IP strategy.